View in EDS

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Saved in:
Bibliographic Details
Title: A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Authors: Jimeno, A.1, Shirai, K.2, Choi, M.3, Laskin, J.4, Kochenderfer, M.5, Spira, A.6,7, Cline-Burkhardt, V.8, Winquist, E.9, Hausman, D.10, Walker, L.10, Cohen, R. B.11
Source: Annals of Oncology. Mar2015, Vol. 26 Issue 3, p556-561. 6p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdu574